Edgewise Therapeutics, Inc. Stock Price, News & Analysis

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement stock option grants on December 31, 2025 to four new non-executive employees totaling 119,250 shares under its 2024 Inducement Equity Incentive Plan. Each option has an exercise price of $24.82, equal to the closing price on the grant date.

Vesting: 25% of each award vests on the one-year employment anniversary, then 1/48th of the shares vest monthly thereafter, subject to continued service. Grants were issued as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (Nasdaq: EWTX) reported completion of CIRRUS-HCM Parts B and C and favorable interim safety from Part D for EDG-7500, a selective oral cardiac sarcomere modulator for obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). Parts B/C enrolled 43 participants across 25 mg, 50 mg and 100 mg cohorts with improvements in NT-proBNP, KCCQ, NYHA and LVOT gradient (oHCM). Part D has >40 participants enrolled; ~70% reached ≥100 mg and 20 participants (8 oHCM, 12 nHCM) completed 12 weeks as of the Dec 23, 2025 cutoff. No clinically meaningful LVEF declines or LVEF <50% were observed. >300 ambulatory monitors captured >2,600 patient-days with no AF/flutter detected during monitoring; one AF event was reported and deemed not related to drug. Full Part D readout expected 2Q 2026; Phase 3 start targeted 4Q 2026.

Edgewise Therapeutics (NASDAQ:EWTX) announced inducement equity grants on November 28, 2025 related to a new non-executive hire. The company granted a stock option to purchase 26,250 shares under its 2024 Inducement Equity Incentive Plan.

The option exercise price is $26.04 per share (equal to the closing price on the grant date). Vesting is 25% after one year and then 1/48th monthly thereafter, subject to continued service. Grants were made as inducements under Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (Nasdaq: EWTX) announced on November 20, 2025 the appointment of Christopher Martin to its Board of Directors.

Mr. Martin brings commercial leadership across marketing, sales, market access, trade and business development and has led multiple product launches. The company said his experience will support preparations for its first commercial launch in Becker muscular dystrophy and efforts to advance its cardiovascular asset to Phase 3. Mr. Martin previously served as Chief Commercial Officer at Verona Pharma, acquired by Merck for approximately $10 billion in October 2025, and held senior commercial roles at SK Life Science, Cempra, Salix Pharmaceuticals and others. He holds a B.S. in Financial Management from Clemson University.

Edgewise Therapeutics (Nasdaq: EWTX) announced on November 12, 2025 that it granted inducement equity awards in connection with the hire of Michael Nofi as Chief Financial Officer, effective the same day. On November 10, 2025 the company granted a stock option to purchase 262,500 shares and an inducement restricted stock unit award covering 43,750 shares under the 2024 Inducement Equity Incentive Plan.

The option’s exercise price is $18.17 per share (equal to the grant‑date closing price). Vesting: options—25% after one year then 1/48th monthly; RSUs—1/4 each year for four years. Awards were granted as inducements per Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (Nasdaq: EWTX) announced the appointment of Michael Nofi as Chief Financial Officer, effective November 10, 2025, and the retirement of current CFO R. Michael Carruthers. Mr. Nofi joins from SpringWorks Therapeutics, where he served as Chief Accounting Officer for six years, and brings over 30 years of finance and accounting leadership in life sciences. The company said Carruthers guided Edgewise through its successful IPO and subsequent financings over the past five years and will support the transition into retirement. Edgewise highlighted Nofi's experience scaling finance operations and preparing organizations for commercialization as relevant as the company advances late-stage clinical programs.

Edgewise Therapeutics (Nasdaq: EWTX) announced management will participate in three investor conference fireside chats in November–December 2025.

Schedule: Guggenheim Healthcare Innovation on Nov 11, 2025 at 8:30 AM ET; Piper Sandler Healthcare on Dec 2, 2025 at 2:00 PM ET; Evercore Healthcare on Dec 3, 2025 at 3:25 PM ET. Webcasts will be available on the company Events & Presentations page and accessible for replay for a limited time. Users are advised to connect several minutes early to ensure timely access to each live webcast.

Edgewise Therapeutics (Nasdaq: EWTX) reported Q3 2025 results and program updates on Nov 6, 2025. Cash and marketable securities were approximately $563.3M as of Sept 30, 2025. The company continues clinical progress across muscular dystrophy and cardiac programs: GRAND CANYON (Becker) enrolled 175 adults with topline expected in Q4 2026; MESA open-label extension is ~99% enrolled. LYNX and FOX Duchenne studies identified a 10 mg dose and plan Phase 3 engagement in 2026. CIRRUS-HCM program update due Q4 2025; EDG-15400 Phase 1 topline expected H1 2026. Q3 operating highlights: R&D expense $37.5M, G&A $9.4M, net loss $40.7M ($0.39 per share).

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity awards on November 3, 2025. On October 31, 2025, the company granted inducement stock options to purchase 170,750 shares to seven new non-executive employees under the 2024 Inducement Equity Incentive Plan.

Each option has an exercise price of $18.28 (equal to the closing price on the grant date). Vesting is 25% after one year, then 1/48th monthly thereafter, subject to continued service. Awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4).